alprazolam FDA Alerts
The FDA Alert(s) below may be specifically about alprazolam or relate to a group or class of drugs which include alprazolam.
MedWatch Safety Alerts are distributed by the FDA and published by Drugs.com. Following is a list of possible medication recalls, market withdrawals, alerts and warnings. For the latest FDA MedWatch alerts, go here.
Recent FDA Alert(s) for alprazolam
Mylan Pharmaceuticals Initiates Voluntary Nationwide Recall of One Lot of Alprazolam Tablets, USP C-IV 0.5 mg, Due to the Potential of Foreign Substance
Oct 26, 2019
Audience: Consumer, Health Professional, Pharmacy
October 26, 2019 -- Mylan Pharmaceuticals Inc. is conducting a voluntary nationwide recall of one lot (see table below) of Alprazolam Tablets, USP C-IV 0.5 mg, to the consumer/user level. This lot is being recalled due to the potential presence of foreign substance. Clinical impact from the foreign material, if present, is expected to be rare, but the remote risk of infection to a patient cannot be ruled out. To date, Mylan has not received any adverse events related to this batch.
Alprazolam Tablets are indicated for the management of anxiety disorder, the short-term relief of symptoms of anxiety, and the treatment of panic disorder, with or without agoraphobia.
Alprazolam Tablets, USP C-IV 0.5 mg, are packaged in bottles of 500. This batch was distributed in the U.S. between July 2019 and August 2019. The recalled lot is as follows:
Product Description and Strength
|0378-4003-05||Alprazolam Tablets, USP C-IV 0.5 mg||Bottles of 500||8082708||September 2020|
Mylan has notified its distributors and customers by letter and is arranging for return of all recalled products. Following are actions for wholesalers, retailers and consumers:
- Wholesaler: Immediately examine your inventory, quarantine and discontinue distribution of these lots. In addition, if you have further distributed the product, please identify your retail level customers and provide a list of customers via Microsoft excel file to email@example.com within 10 business days. Stericycle will notify your retail level customers that received the affected batches.
- Retailer: Immediately examine your inventory, quarantine and discontinue distribution of these lots. Additionally, if you have further distributed the product, please identify the consumer and notify them immediately of this product recall. The consumer should be instructed to contact Stericycle at 1-888-843-0255 for the documentation packet to return the product.
- Consumer: Please contact Stericycle at 1-888-843-0255 for the documentation packet to return product to Stericycle.
Consumers with questions regarding this recall can contact Mylan Customer Relations at 800.796.9526 or firstname.lastname@example.org, Monday through Friday from 8 a.m. – 5 p.m. EST. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to using this drug product.
Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.
- Complete and submit the report Online
- Regular Mail or Fax: Download form or call 1- 800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
This recall is being conducted with the knowledge of the U.S. Food and Drug Administration
Feb 16, 2007
Audience: Consumers, healthcare professionals[Posted 02/16/2007] FDA informed consumers and healthcare professionals regarding the possible dangers of buying prescription medications online. Individuals who ordered Ambien, Xanax, Lexapro, and Ativan over the internet received a product that contained haloperidol, a powerful anti-psychotic drug. Several consumers experienced difficulty in breathing, muscle spasms and muscle stiffness after ingesting the suspect product and had to seek emergency medical treatment. Haloperiodol can cause muscle stiffness, spasms, agitation and sedation. Taking medication that contains an active ingredient other than what is prescribed by qualified healthcare professionals is generally unsafe. FDA urges consumers to review the FDA website for additional information prior to making purchases of medications over the internet (http://www.fda.gov/ForConsumers/ProtectYourself/default.htm).
[February 16, 2007 - News Release - FDA]
More alprazolam Resources
- Alprazolam Consumer Information
- Alprazolam Extended-Release Tablets Consumer Information
- Alprazolam Orally Disintegrating Tablets Consumer Information
- Alprazolam Tablets Consumer Information
- Alprazolam Oral Solution Consumer Information
- Alti-Alprazolam Oral Advanced Consumer Information
- Gabazolamine-0.5 Oral Advanced Consumer Information
- Alprazolam Oral Advanced Consumer Information
- Alprazolam AHFS DI Monograph
- Alprazolam Prescribing Information
- Alprazolam Extended Release Prescribing Information
- Alprazolam ODT Prescribing Information
- Alprazolam XR Prescribing Information
- ALPRAZolam A-Z Drug Facts